Claims for Patent: 8,728,806

Summary for Patent: 8,728,806

Title:	Methods and compositions related to T.sub.h-1 dendritic cells
Abstract:	Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition encoding one or more tumor antigens and loaded with a corresponding tumor antigen composition.
Inventor(s):	Decker; William K. (Houston, TX), Shpall; Elizabeth J. (Houston, TX), Komanduri; Krishna V. (Village of Palmetto Bay, FL), Xing; Dongxia (The Woodlands, TX)
Assignee:	The Board of Regents, The University of Texas System (Austin, TX)
Application Number:	13/132,517
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,728,806
Patent Claims:	1. A method for inducing an immunonologic response in a patient comprising: (a) obtaining monocytic dendritic cell precursors from the patient; (b) culturing the monocytic dendritic cell precursors to induce differentiation into immature dendritic cells; (c) differentiating the immature dendritic cells into mature dendritic cells by (i) transfecting into the immature dendritic cells a nucleic acid composition encoding one or more tumor antigens; and (ii) contacting the immature dendritic cells with a tumor antigen composition, wherein a tumor antigen of the tumor antigen composition comprises an epitope having a sequence that overlaps minimum of 5 amino acids with the sequence of an epitope of a tumor antigen encoded by the nucleic acid composition of step (i) but is not identical thereto; (d) culturing the immature dendritic cells to produce mature dendritic cells; and (e) administering the mature dendritic cells to the patient. 2. The method of claim 1, wherein the mature dendritic cells are selected for CD83 expression, wherein the selected mature dendritic cells are enriched for cells expressing increased levels of CD83 as compared to reference dendritic cells contacted with a tumor antigen composition and not a nucleic acid composition. 3. The method of claim 2, wherein CD83 expression is at least 10-40% higher than the reference dendritic cells. 4. The method of claim 1, wherein the immature dendritic cells are subjected to negative selection using an agent that binds a non-target dendritic cell. 5. The method of claim 4, wherein the agent is an antibody that binds an HLA allele. 6. The method of claim 5, wherein the HLA allele is a HLA-DR, HLA-DO, or HLA-DQ. 7. The method of claim 5, wherein the HLA allele is HLA-DR. 8. The method of claim 1, wherein the immature dendritic cells are subjected to positive selection using an agent that binds a target immature dendritic cell. 9. The method of claim 8, wherein the agent binds CD40, CD83, IL-2.beta. and/or TLR-4. 10. The method of claim 1, wherein the nucleic acid composition comprises total nucleic acid from a tumor source. 11. The method of claim 1, wherein the nucleic acid composition comprises mRNA isolated from a tumor source. 12. The method of claim 11, wherein the isolated mRNA is enriched for mRNA encoding tumor specific antigens. 13. The method of claim 12, wherein the isolated mRNA is subjected to mRNA subtraction using non-tumor cell RNA. 14. The method of claim 1, wherein the tumor antigen composition is an enriched tumor antigen composition. 15. The method of claim 14, wherein the enriched tumor antigen composition comprises a cellular fraction from cells of a tumor source. 16. The method of claim 14, wherein the cells from the tumor source are selected by removing cells expressing proteins that are typically not expressed or expressed at significantly reduced levels in a tumor cell. 17. The method of claim 14, wherein the cells from the tumor source are selected using cell surface markers preferentially expressed by tumor cells. 18. The method of claim 14, wherein the enriched tumor antigen composition comprises one or more protein fractions of a tumor cell lysate. 19. The method of claim 18, wherein the enriched tumor antigen composition is produced by contacting a tumor cell lysate with a protein array that preferentially binds non-tumor specific antigens. 20. The method of claim 1, wherein the nucleic acid composition comprises an expression construct. 21. The method of claim 20, wherein the expression construct encodes one or more tumor antigen. 22. The method of claim 21, wherein the encoded tumor antigen is selected from the group consisting of 707-AP (707 alanine proline), AFP (alpha (.alpha.)-fetoprotein), AIM-2 (interferon-inducible protein absent in melanoma 2), ART-4 (adenocarcinoma antigen recognized by T cells 4), BAGE (B antigen), Bcr-abl (breakpoint cluster region-Abelson), CAMEL (CTL-recognized antigen on melanoma), CAP-1 (carcinoembryonic antigen peptide-1), CASP-8 (caspase-8), CDC27 (cell-division-cycle 27), CDK4 (cyclin-dependent kinase 4), CEA (carcino-embryonic antigen), CLCA2 (calcium-activated chloride channel-2), CT (cancer/testis antigen), Cyp-B (cyclophilin B), DAM (differentiation antigen melanoma (DAM-6 and DAM-10)), ELF2 (elongation factor 2), Ep-CAM (epithelial cell adhesion molecule), EphA2, 3 (Ephrin type-A receptor 2, 3), ETV6-AML1 (Ets variant gene 6/acute myeloid leukemia 1 gene ETS), FGF-5 (Fibroblast growth factor-5), FN (fibronectin), G250 (glycoprotein 250), GAGE (G antigen), GnT-V (N-acetylglucosaminyltransferase V), Gp100 (glycoprotein 100 kD), HAGE (helicase antigen), HER-2/neu (human epidermal receptor-2/neurological), HLA-A*0201-R170I (arginine (R) 170 to isoleucine (I) substitution in the HLA-A2 gene), HSP70-2M (heat shock protein 70-2 mutated), HST-2 (human signet ring tumor-2), hTERT (human telomerase reverse transcriptase), iCE (intestinal carboxyl esterase), IL-13R.alpha.2 (interleukin 13 receptor .alpha.2 chain), KIAA0205; LAGE (L antigen); LDLR/FUT (low density lipid receptor/GDP-L-fucose: .beta.-D-galactosidase 2-.alpha.-L-fucosyltransferase), MAGE (melanoma antigen), MART-1/Melan-A (melanoma antigen recognized by T cells-1/Melanoma antigen A), MART-2 (melanoma antigen recognized by T cells-2), MC1R (melanocortin 1 receptor), M-CSF (macrophage colony-stimulating factor gene), MUC1, 2 (mucin 1, 2), MUM-1, -2, -3 (melanoma ubiquitous mutated 1, 2, 3), NA88-A (NA cDNA of patient M88), Neo-PAP (Neo-poly(A) polymerase), NPM/ALK (nucleophosmin/anaplastic lymphoma kinase fusion protein), NY-ESO-1 (New York--esophageous 1), OA1 (ocular albinism type 1 protein), OGT (0-linked N-acetylglucosamine transferase gene), OS-9; P15 (protein 15); p190 minor bcr-abl (protein of 190 KD bcr-abl), Pml/RAR.alpha. (promyelocytic leukemia/retinoic acid receptor .alpha.), PRAME (preferentially expressed antigen of melanoma), PSA (prostate-specific antigen), PSMA (prostate-specific membrane antigen), PTPRK (receptor-type protein-tyrosine phosphatase kappa), RAGE (renal antigen), RU1, 2 (renal ubiquitous 1, 2), SAGE (sarcoma antigen), SART-1, -2, -3 (squamous antigen rejecting tumor 1, 2, 3), SSX-2 (synovial sarcoma, X breakpoint 2), Survivin-2B (intron 2-retaining survivin), SYT/SSX (synaptotagmin I/synovial sarcoma, X fusion protein), TEL/AML1 (translocation Ets-family leukemia/acute myeloid leukemia 1), TGF.beta.RIII (transforming growth factor .beta. receptor 2), TPI (triosephosphate isomerase), TRAG-3 (taxol resistant associated protein 3), TRG (testin-related gene), TRP-1 (tyrosinase related protein 1), TRP-2 (tyrosinase related protein 2), TRP-2/INT2 (TRP-2/intron 2), TRP-2/6b (TRP-2/novel exon 6b), PAP (prostatic acid phosphatase); PR1 (proteinase 3); and WT1 (Wilms' tumor gene). 23. The method of claim 1, further comprising screening a patient or patient tumor for expression of one or more tumor antigens. 24. The method of claim 23, wherein an expression construct expressing the identified tumor antigen is transfected into the immature dendritic cell. 25. The method of claim 23, wherein the immature dendritic cell is contacted with a tumor antigen composition comprising a recombinant identified tumor antigen. 26. The method of claim 1, wherein the nucleic acid composition encodes components of the tumor antigen composition. 27. The method of claim 1, wherein the immature dendritic cells are transfected with the nucleic acid composition prior to contact with the tumor antigen composition. 28. The method of claim 1, wherein the immature dendritic cells are contacted with the tumor antigen composition prior to transfection with the nucleic acid composition. 29. The method of claim 1, wherein the immature dendritic cells are simultaneously transfected with the nucleic acid composition and contacted with the tumor antigen composition. 30. The method of claim 20, wherein the tumor is renal cell cancer, melanoma, prostate cancer or chronic lymphocytic leukemia.

Details for Patent 8,728,806

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26